Managing anxiety to improve asthma treatment adherence
Official title: Remote Management Strategies and Adherence Improvement for Anxiety-related ICS Resistance in Asthma Patients: an Open-label, Multicenter, Randomized Controlled Trial
Run by First Affiliated Hospital of Ningbo University · NCT06732141 · Data updated 2026-11-12
This study is testing whether a personalized phone program that helps manage anxiety can improve medication use in adults with asthma who struggle to take their inhalers regularly.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 216 (estimated) |
| Sponsor | First Affiliated Hospital of Ningbo University Research network |
| Locations | 11 sites (Harbin and 10 other locations) |
| Status | Recruiting |
| Started | December 13, 2024 |
| Main results expected | February 28, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | June 18, 2026 |
| Trial ID | NCT06732141 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with asthma who have been on ICS therapy for at least six months and experience clinically significant anxiety.
✕Probably not a fit
Patients with acute asthma exacerbations or those not experiencing anxiety related to ICS use may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS) aims to enhance medication adherence and manage anxiety in asthma patients who struggle with inhaled corticosteroid (ICS) use due to anxiety. This multicenter, open-label, randomized controlled trial will enroll 216 adult participants with poor ICS adherence and clinically significant anxiety. Participants will receive personalized telephone-based interventions, including medication education, progressive muscle relaxation, motivational interviewing, and lung rehabilitation guidance, compared to standard care with weekly follow-up calls.
Why it matters
Potential benefit: If successful, this study could significantly improve asthma management and quality of life for patients who are anxious about their medication.
How similar studies have gone: While there is limited data on similar approaches, the integration of psychological support in chronic disease management has shown promise in other contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age Requirement: Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions. 2. Diagnosed Asthma: 1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months. 2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects. 3. ICS Treatment History: 1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation. 2. No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes. 4. Poor Medication Adherence: Identified using the Medication Adherence Report Scale (MARS-10), with an average score \<4.5, indicating suboptimal adherence. 5. Presence of Anxiety Symptoms: 1. Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety. 2. Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues. 6. Ability to Communicate by Phone: Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions. 7. Stable Health Condition: Asthma status must be stable, with no acute exacerbations or significant changes in the past month. Exclusion Criteria: 1. Severe Psychiatric or Cognitive Disorders: 1. Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria. 2. Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention. 3. Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes. 2. Substance Abuse or Dependence: History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances. 3. Severe Comorbidities: 1. Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health. 2. Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes. 4. Pregnancy or Lactation: Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations. 5. Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions: Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects. 6. Participation in Other Interventional Clinical Trials: Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes. 7. Incompatibility with Telephone-Based Interventions: Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons. 8. Adverse Reactions to Psychological Interventions: Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study. 9. History of Major Surgery or Hospitalization: History of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.
Where it's running
-
Second Affiliated Hospital of Harbin Medical University
Harbin, China Recruiting -
Anhui Chest Hospital
Hefei, China Recruiting -
The First Affiliated Hospital of Anhui Medical University
Hefei, China Recruiting -
The Second Affiliated Hospital of Anhui Medical University
Hefei, China Recruiting -
Jingzhou Central Hospital
Jingzhou, China Recruiting -
Ningbo Medical Center Lihuili Hospital
Ningbo, China Recruiting
Show 5 more locations
-
Qianhu Hospital
Ningbo, China Recruiting -
The First Affiliated Hospital of Ningbo University
Ningbo, China Recruiting -
Ninghai County First Hospital
Ninghai, China Recruiting -
Haishu District People's Hospital
Ningbo, China Not yet recruiting -
Taizhou Central Hospital
Taizhou, China Not yet recruiting
Study contacts
- Study coordinator: Chao Cao
- Email: caocdoctor@163.com
- Phone: +86-0574-87089878
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.